Related Experiment Videos
Buserelin in premenstrual syndrome.
S Y Hussain1, J H Massil, W H Matta
1Academic Department of Obstetrics and Gynaecology, Royal Free Hospital Medical School, London, UK.
Summary
Buserelin nasal spray reduced peak premenstrual syndrome symptoms in a small study. However, underlying symptoms worsened, and side effects may limit long-term use of this luteinizing hormone-releasing hormone agonist.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Premenstrual syndrome (PMS) significantly impacts women's quality of life.
- Hormonal therapies are explored for managing PMS symptoms.
- Luteinizing hormone-releasing hormone (LHRH) agonists offer a potential mechanism for ovarian cycle modulation.
Purpose of the Study:
- To evaluate the efficacy and impact of nasal buserelin on premenstrual syndrome symptoms.
- To assess changes in symptom severity and overall well-being during treatment.
- To identify potential limitations for long-term buserelin use in PMS management.
Main Methods:
- A cohort of 16 patients with PMS received 900 micrograms of nasal buserelin daily.
- Symptom severity was measured daily using the Visual Analogue Scale (VAS).
- Trigg's trend analysis was employed to analyze symptom changes (ESAmax, ESAmin, ESAdelta, Gmax, Gmin, Gdelta).
Main Results:
- Buserelin treatment led to a reduction in peak symptom severity (ESAmax) and maximum global scores (Gmax).
- Conversely, minimum symptom scores (ESAmin) and minimum global scores (Gmin) increased, indicating potential worsening of underlying symptoms.
- Significant reductions were observed in delta scores for depression, bloating, breast symptoms, and global scores (p < 0.05), but these worsened during follow-up.
Conclusions:
- Nasal buserelin demonstrated a reduction in peak PMS symptom severity but also an increase in underlying symptom intensity.
- Observed side effects and symptom worsening during follow-up suggest limitations for long-term buserelin therapy.
- Combination therapy with additional hormonal treatments might be necessary to facilitate sustained long-term management of PMS.